Skip to main content

Table 4 Treatment response

From: Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature

ERKD treatment response Post ERKD treatment
Pt. no. ERKD monotherapy or multimodality treatment CR, PR, Stable Duration of response Modality Response
1 ERKD Mono-TX Progression   Avastin Clinical neurological deterioration, ↑blindness
2 ERKD Mono-TX Stable at 6 weeks; progression at 12 weeks 6 weeks Decadron  
3 Mono-TX Stable 5 years remission None Remission 5 years. Good quality of life
4 Multi modal with Chemo-TX Stable ? 4 years remission Chemo-TX 4 years remission good quality of life
5 Multi modal Rad-TX and TMZ CR 4 months CPT-11 Bevacizumab  
6 ERKD and Vinblastine Stable >12 months   
7 ERKD and Avastin Stable 4 months Decadron